Sadly @RepDianaDeGette does NOT support terminally ill Coloradans' battle to receive effective new ALS treatments via HR.7071 & EAP grants...she says NIH's current ALS resources are "already adequate". They're NOT. Plz tell those waiting below: #ALS@KDVR @CBSDenver #ENDALS@NIH
Amyotrophic Lateral Sclerosis (ALS) Markets – $1.04 Billion Opportunity Analysis and Forecasts to 2029: Biogen, Mitsubishi, and BrainStorm are Forecast to Lead the ALS Market – https://t.co/8vPVgQlQhj https://t.co/m2JXH6ruYB